|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Genentech |
| Information provided by: | Genentech |
| ClinicalTrials.gov Identifier: | NCT00096967 |
Purpose
This is a multicenter, open-label extension study. Subjects who have received rhuMAb VEGF therapy in Study AVF2107g, AVF2119g, or AVF2192g and who completed the parent study are eligible for inclusion in this trial. Subjects who have received placebo in Study AVF2107g or AVF2192g are also eligible.
| Condition | Intervention | Phase |
|
Breast Cancer Colorectal Cancer Metastases |
Drug: Avastin (bevacizumab) |
Phase III |
| Genetics Home Reference related topics: | breast cancer |
| MedlinePlus related topics: | Breast Cancer Cancer Colorectal Cancer |
| ChemIDplus related topics: | Bevacizumab |
| Study Type: | Interventional |
| Study Design: | Treatment, Open Label |
| Official Title: | An Open-Label, Multicenter Extension Study of rhuMAb VEGF (Bevacizumab) in Subjects Treated in a Previous Genentech-Sponsored Cancer Study |
Eligibility
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations
More Information
Study Results 
  |
| Study ID Numbers: | AVF2540g |
| First Received: | November 17, 2004 |
| Last Updated: | June 23, 2005 |
| ClinicalTrials.gov Identifier: | NCT00096967 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|
|
|